Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Results from GenVec's phase I trial of its HIV vaccine, presented at the AIDS Vaccine 2006 Conference in Amsterdam this week, show that the company's adenovector-based technology was well tolerated and evinced signs of efficacy.
Subscribe to our email newsletter
Results were consistent with previously reported data, showing immune responses when the vaccine was used alone or in combination with a DNA primer vaccine.
In a study of the HIV vaccine, incorporating GenVec’s adenovector-based technology, 40 volunteers showed stimulation of T-cells against the multiple antigens contained in this vaccine.
The study was presented by Dr Larry Peiperl of University of California School of Medicine, and the study was conducted by the HIV Vaccine Trials Network.
In a second study presented by Dr Richard Koup of the Vaccine Research Center (VRC), cellular immune responses were analyzed in 14 volunteers given a DNA prime followed by a boost with the HIV vaccine incorporating GenVec’s adenovector technology. Dr Koup reported that this data indicated that the combination of priming and boosting produces more polyfunctional T-cells than either modality alone.
“Polyfunctional T-cells are a hallmark of existing vaccines such as the effective smallpox vaccine and are also believed to be important for an effective HIV vaccine. A similar breadth of polyfunctional T-cells occurs in patients who have HIV but do not progress rapidly to AIDS,” commented Dr Rick King, GenVec’s senior VP of Research.